Welcome to The Ammon-Pinizzotto Center for Women’s Mental Health at MGH. Our Center, established in 1989, has been renamed following the generous gift from Carol Ammon and Dr. Marie Pinizzotto. These resources will be used to realize the overarching mission of the Center.
This website provides a range of current information including discussion of new research findings in women’s mental health and how such investigations inform day-to-day clinical practice. Despite the growing number of studies being conducted in women’s health, the clinical implications of such work are frequently controversial, leaving patients with questions regarding the most appropriate path to follow. Providing these resources to patients and their doctors so that individual clinical decisions can be made in a thoughtful and collaborative fashion dovetails with the mission of our Center.
All pregnant women ages 18-45 are eligible to enroll in the registry. We are currently seeking both controls and those being treated with atypical antipsychotics and/ or antidepressants.
This study will involve 3 brief phone interviews over an 8-month period. The National Pregnancy Registry for Psychiatric Medications is dedicated to evaluating the safety of psychiatric medications that may be taken by women during pregnancy to treat a wide range of mood, anxiety, or psychiatric disorders. The primary goal of this Registry is to determine the frequency of major malformations, such as heart defects, cleft lip, or neural tube defects, in infants exposed to atypical antipsychotics and antidepressants during pregnancy. For more information, please call 1-866-961-2388 or e-mail firstname.lastname@example.org.
Help make the future better for many other women like you.
The MGH Center for Women’s Mental Health
Perinatal and Reproductive Psychiatry Program
Simches Research Building
185 Cambridge St Suite 2200
Boston, MA 02114
To make an appointment:
Massachusetts General Hospital Clinical Program: (617) 724-7792
Location of appointments:
Wang Ambulatory Care Center, Massachusetts General Hospital
15 Parkman St., Floor 8
Boston, MA 02114-3117
July 21, 2016
Researchers from the University of North Carolina’s School of Medicine and the Postpartum Depression: Action Towards Causes and Treatment Consortium have just released a free iPhone app which new mothers can use to diagnose postpartum depression. PPD ACTTM surveys women to identify those who have had symptoms of PPD. The app also will invite certain women based on ...Read more
July 19, 2016
Serotonin reuptake inhibitor (SRI) antidepressants may affect platelet aggregation and thus may increase the risk of bleeding. Several studies have sought to determine if exposure to SSRI antidepressants in late pregnancy is associated with an increased risk of postpartum hemorrhage. The most recent study was a population-based cohort study including 225,973 women with a total of ...Read more
July 18, 2016
As we move toward universal screening for perinatal depression, one of our most significant challenges will be to evaluate and deliver care to the women who are identified as being depressed. It is discouraging to note that recommendations regarding screening have not necessarily resulted in increased rates of treatment in women with perinatal depression. Dr. ...Read more
July 15, 2016
This week a study published by Kieviet and colleagues gives us more information on the mechanism of poor neonatal adaptation in infants prenatally exposed to SSRIs and suggests that levels of maternal psychological distress modulate this risk. Pugh and colleagues assessed the effectiveness of internet-delivered CBT for the management of perinatal depression. A Randomised Controlled Trial ...Read more
July 12, 2016
About a year ago, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of severe postpartum depression. SAGE-547 is a new drug, an allosteric modulator of GABAA receptors, which was initially under investigation for the treatment of refractory seizure disorders. It turns out that SAGE-547 may also be useful for the ...Read more
New Research from the CWMH: Evaluating the Risk of Major Malformations in Children Prenatally Exposed to Atypical Antipsychotics
July 11, 2016
Despite the increasing use of the newer “atypical” or second-generation antipsychotic agents to treat a spectrum of psychiatric disorders, including schizophrenia, bipolar disorder, major depression, PTSD and other anxiety disorders, we have relatively little data on the reproductive safety of these newer atypical agents. In response to this deficit, the National Pregnancy Registry for Atypical Antipsychotics ...Read more